Skip to main
MBX

MBX Stock Forecast & Price Target

MBX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 10%

Bulls say

MBX Biosciences is a biopharmaceutical company with a strong pipeline and promising early data for their lead asset, canvuparatide, in the treatment of hypoparathyroidism. With a differentiated platform and novel treatment approach, the company shows potential for significant upside in the market. Despite initial market reaction to early data, analysts remain bullish on the potential of MBX 4291 and canvuparatide, projecting peak sales in the billions.

Bears say

MBX Biosciences is at a critical stage with one product in Phase 1 trials and another in Phase 2 trials, with a high risk of failure and low likelihood of profitability in the near future. Additionally, the company's product candidates face strong competition, and their efficacy and safety profiles are not significantly better than existing therapies in the same class. The company's current valuation is largely speculative, and its long-term success is uncertain.

MBX has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 10% predict a Strong Sell.

This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MBX Biosciences Inc (MBX) Forecast

Analysts have given MBX a Buy based on their latest research and market trends.

According to 10 analysts, MBX has a Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MBX Biosciences Inc (MBX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.